Fig. 5From: Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adultsChanges in lipid, kidney and liver profiles at 48 weeks. RPV rilpivirine, EFV efavirenz, PI protease inhibitor, LDL low density lipoprotein, HDL high density lipoprotein, ALT alanine aminotransferaseBack to article page